logo

For the Inventor, By the Inventor

Middlesex, United Kingdom

Glaxosmithkline Intellectual Property Development Limited


USPTO Granted Patents = 230



Forward Citations = 560

Loading Chart...
Loading Chart...

556 inventors (with patents filed for the assignee):

goldMedal Niall Andrew Anderson (14 out of 14 patents)

silverMedal Alan Peter Lewis (12 out of 25 patents)

bronzeMedal Julie Nicole Hamblin (12 out of 31 patents)

4.  Bryan Wayne King (12 out of 12 patents)

5.  Joshi M Ramanjulu (11 out of 18 patents)

6.  Adam Kenneth Charnley (10 out of 10 patents)

7.  Jeffrey K Kerns (10 out of 17 patents)

8.  Zehong Wan (10 out of 35 patents)

9.  Joelle Le (10 out of 23 patents)

10.  Michael P DeMartino (10 out of 10 patents)

11.  John Martin Pritchard (10 out of 10 patents)

12.  Joseph J Romano (9 out of 14 patents)

13.  Nigel James Parr (9 out of 19 patents)

14.  Linda N Casillas (9 out of 15 patents)

15.  Hilary Schenck Eidam (9 out of 16 patents)


Core Competencies:
Cell Migration Assays
DNMT1 Inhibitors
Oligonucleotide Production
cGAS Inhibitors
Anti-BCMA Antibody Therapy
STING Agonists
Protein Modulators
HIV Therapy Compounds
Furin Inhibitors
Targeted Protein Degradation
Inflammatory Disorder Treatments
Antibody Variants

230 patents:

1. 12360102 - High-throughput assay for cell migration, chemotaxis, and function (2025-07-15),
2. 12351597 - Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH (2025-07-08),
3. 12339215 - Method for determining the viability of cells (2025-06-24),
4. 12331327 - Carboxyesterase biocatalysts (2025-06-17),
5. 12297223 - Compounds (2025-05-13),
6. 12285436 - Substituted pyridines as DNMT1 inhibitors (2025-04-29),
7. 12275983 - Processes for the production of oligonucleotides (2025-04-14),
8. 12247033 - Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors (2025-03-11),
9. 12234293 - Treatment for primary amyloidosis with anti-BCMA binding protein (2025-02-25),
10. 12227585 - Anti-BCMA antibody drug conjugate combination treatment for cancer (2025-02-18),
11. 12221444 - 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use (2025-02-11),
12. 12178851 - Methods for administering STING agonists (2024-12-31),
13. D1053891 - Display screen with graphical user interface (2024-12-10),
14. 12122828 - IL-7 binding proteins and their use in medical therapy (2024-10-22),
15. 12043436 - Modular aseptic production system (2024-07-23),
GlaxoSmithKline Intellectual Property Development Limited is a leading global pharmaceutical company that focuses on the research, development, and commercialization of innovative medicines, vaccines, and consumer healthcare products. They are committed to improving the quality of human life by delivering sustainable healthcare solutions. With a diverse portfolio and extensive expertise, they address various therapeutic areas and serve millions of patients worldwide. For more information, visit their website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

...
230 Patents

#3 in Middlesex

#69 in United Kingdom

#3,610 in the World

...
Middlesex, United Kingdom

Glaxosmithkline Intellectual Property Development Limited

Forward Citations = 560

556 inventors:

goldMedal Niall Andrew Anderson (14 out of 14 patents)

silverMedal Alan Peter Lewis (12 out of 25 patents)

bronzeMedal Julie Nicole Hamblin (12 out of 31 patents)

4.  Bryan Wayne King (12 out of 12 patents)

5.  Joshi M Ramanjulu (11 out of 18 patents)

Please report any incorrect information to support@idiyas.com
Loading…